A new trading day began on Monday, with CytomX Therapeutics Inc (NASDAQ: CTMX) stock price down -5.28% from the previous day of trading, before settling in for the closing price of $2.65. CTMX’s price has ranged from $0.40 to $2.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 19.16% over the past five years. Meanwhile, its annual earnings per share averaged -124.50%. With a float of $131.09 million, this company’s outstanding shares have now reached $157.54 million.
Let’s look at the performance matrix of the company that is accounted for 121 employees. In terms of profitability, gross margin is 64.9%, operating margin of 24.37%, and the pretax margin is 28.35%.
CytomX Therapeutics Inc (CTMX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 16.79%, while institutional ownership is 35.39%. The most recent insider transaction that took place on Mar 18 ’25, was worth 22,556. In this transaction CEO of this company sold 37,656 shares at a rate of $0.60, taking the stock ownership to the 995,195 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Financial Officer sold 8,551 for $0.60, making the entire transaction worth $5,122. This insider now owns 201,026 shares in total.
CytomX Therapeutics Inc (CTMX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -124.50% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Here are CytomX Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.50, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 3.91 million, a positive change from its year-to-date volume of 3.63 million. As of the previous 9 days, the stock’s Stochastic %D was 79.34%. Additionally, its Average True Range was 0.27.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 87.19%, which indicates a significant increase from 67.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 126.43% in the past 14 days, which was lower than the 168.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.15, while its 200-day Moving Average is $1.04. Nevertheless, the first resistance level for the watch stands at $2.74 in the near term. At $2.96, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.11. If the price goes on to break the first support level at $2.37, it is likely to go to the next support level at $2.22. Assuming the price breaks the second support level, the third support level stands at $2.00.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
With a market capitalization of 395.44 million, the company has a total of 80,621K Shares Outstanding. Currently, annual sales are 138,100 K while annual income is 31,870 K. The company’s previous quarter sales were 50,920 K while its latest quarter income was 23,530 K.
